Printer Friendly

Nanobac Life Sciences', Neva Ciftcioglu, Awarded the M. Kemal Ataturk's Daughter Science Award by the Halic Rotary Club; Ceremony Performed at Nasa Johnson Space Center.

TAMPA, Fla. -- Nanobac Life Sciences, Inc. (OTCBB:NNBP.OB) announces that on Monday, December 6, 2004, Nanobac's Director of Science, Dr. Neva Ciftcioglu was presented with the M. Kemal Ataturk's Daughter Science Award by the Halic Rotary Club in Istanbul, Turkey as part of the 100 year celebration of the Rotary Clubs. The Award Ceremony was organized and presented by Melih Berk, the past president of Halic Rotary Club and a member of the Advisory Board of the Turkish Forum. The timing of the award coincided with the 70th anniversary of women's suffrage in Turkey, granted under the leadership of Mustafa Kemal Ataturk.

Dr. Neva Ciftcioglu is Nanobac's Director of Science and is on loan to NASA under a Space Act Agreement to work on Nanobacteria and exobiological research at NASA's Johnson Space Center in Houston, Texas. Dr. Ciftcioglu has won awards from institutions in Europe and the United States.

"It is especially gratifying to know that the award Neva received was named after such a visionary as Mustafa Kemal Ataturk," stated Mr. Stanton, CEO of Nanobac. He also stated, "We are pleased to have Dr. Ciftcioglu on our team and we believe Neva's continuing pioneering work for the welfare of mankind will lead to treatments for the many pathological calcification diseases, such as heart disease, kidney stones and prostatitis."

About Nanobac Life Sciences

Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of Nanobacterium sanguineum (Nanobacteria). The Company's pioneering research is establishing the pathogenic role of Nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to treat nanobacterial infection. The Company currently markets a patented nanobiotic regimen. For further information concerning our nanobiotic, please visit

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at:

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 20, 2004
Previous Article:Alcoa Wheels Drive New Ford Designs.
Next Article:Mellon Research, Inc retained, Morgan Phillip's.

Related Articles
Springfield High School.
Willamette High School.
SAIC wins NASA IT services contract.
Shooting for the moom.
The National Archive at Girne--II.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters